Duchenne Muscular Dystrophy clinical trials at UC Davis
2 research studies open to eligible people
Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)
open to eligible males ages 2 years and up
This is an open-label gene transfer therapy study evaluating the safety of and expression from delandistrogene moxeparvovec in participants with DMD. The maximum participant duration for this study is 156 weeks.
Sacramento, California and other locations
EDG-5506 in Children and Adolescents With Duchenne Muscular Dystrophy Previously Treated With Gene Therapy
“Volunteer for research to contribute to discoveries that may improve child and adolescent DMD for you, your family, and your community!”
open to eligible males ages 6-17
The FOX study is a 2-part, multicenter, Phase 2 study of safety, pharmacokinetics, and biomarkers in children and adolescents with Duchenne muscular dystrophy previously treated with gene therapy including a randomized, double-blind, placebo-controlled Part A, followed by an open-label part B.
Sacramento, California and other locations
Our lead scientists for Duchenne Muscular Dystrophy research studies include Craig McDonald, MD.
Last updated: